HRT and breast cancer risk: Preamble of the recommendations of clinical practices, biological data;THS et risque de cancer du sein: Préambule des recommandations des pratiques cliniques, données biologiques

Reproduction Humaine et Hormones

Volumn 20, Issue 5, 2007, Pages 333-341

  Brettes, Jean Philippe ^a   Mathelin, Carole ^a   Gorins, André ^a,b  

^a HÔPITAL CIVIL   (France)

^b NONE   (France)

Author keywords

BRCA 1 gene; Breast cancer; Hormonal risk factors; Polymorphism

Indexed keywords

ANDROGEN; BRCA1 PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANDROGEN SYNTHESIS; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; MAMMOGRAPHY; MENOPAUSE; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

EID: 38549141075     PISSN: 09943919     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. DUNNING AM, HEALEY CS, PHAROAH PDP, TEARE MD, PONDER BAJ, EASTON DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 1999, 8, 843-854.
2. YAGER JD, DAVIDSON NE. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 2006, 354, 270-282.
3. es Journées de la SFSPM, Nancy, novembre 2004, 22-45.
4. LIPPERT TH, SEEGER H, MUECK AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women. Horm. Metab. Res. 1998, 30: 598-600.
5. LIEHR JG. Is estradiol a genotoxic mutagenic carcinogen. Endrocrine Reviews 2000, 21: 40-54.
6. MUECK AO, SEEGER H, WALLWIENER D. Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas 2002, 43: 87-93.
7. BENTZ AT, SCHNEIDER C.M, WESTERLIND KC. The relationship between physical activity and 2-hydroxyestrone, 16α-hydroxyestrone, and the 2/16 ratio in premenopausal women (United States). Cancer Causes Control 2005, 16: 455-461.
8. SEEGER H, WALLWIENER D, KRAEMER E, MUECK AO. Comparison of possible carcinogenic estradiol metabolites : effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006, 54 : 72-77.
9. SEEGER H, DEURINGER FU, WALLWIENER D, MUECK AO. Breast cancer risk during HRT: influence of estradiol metabolites on breast cancer and endothelial cell proliferation. Maturitas 2004, 49: 235-240.
10. THE ENDOGENOUS HORMONES AND BREAST CANCER COLLABORATIVE GROUP. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002, 94: 606-616.
11. CAULEY JA, LUCAS FL, KULLER LH, STONE K. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann. Intern. Med. 1999, 130 : 270-277.
12. HUNTER DJ, SPIEGELMANN D, ADAMI HO. et al. Non-dietary factors as risk factors for breast cancer, and as effect modifiers of the association of fat intake and risk of breast cancer. Cancer Causes Control 1997, 8: 49-56.
13. KELSEY JL, BERNSTEIN L. Epidemiology and prevention of breast cancer. Annu. Rev. Public Health 1996, 17: 47-67.
14. COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER. Breast cancer and hormone replacement therapy : collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 1997, 350: 1047-1059.
15. GUTHRIE JR, DENNERSTEIN L, TAFFE JR, EBELING PR, RANDOLPH JF, BURGER HG. Graisse abdominale centrale et hormones endogènes pendant la transition ménopausique. Fertil. Steril. 2003, 79: 1335-1340.
16. AGARWAL VR, ASHANULLAH CI, SIMPSON ER, BULUN SE. Alternative spliced transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of women* J. Clin. Endocrinol. Metab. 1997, 82: 70-74.
17. BIANCHINI F, KAAKS R, VAINIO H. Overweith, obesity, and cancer risk. Lancet Oncol 2002, 3: 565-574.
18. PROBST-HENSCH NM, INGLES SA, DIEP AT, HAILE RW, STANCZYK F.Z, KOLONEL N.L, HENDERSON. Aromatase and breast cancer susceptibility. Endocrine-Related Cancer 1999, 6, 165-173.
19. BRODIE A, LU Q, NAKAMURA J. Aromatase in the normal breast and breast cancer. J. Steroid Biochem. Molec. Biol. 1997, 61: 281-286.
20. MASAMURA S, SANTNER SJ, GIMOTTY P, GEORGE J, SANTEN RJ. Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function : Role of very high affinity tissue uptake. Breast Cancer Res. Treat. 1997, 42: 215-226.
21. THIJSSEN JH.H. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas 2004, 49: 25-33.
22. DOWSETT M, FOLKERD E, DOODY D, HAYNES B. The biology of steroid hormones and endocrine treatment of breast cancer. The Breast 2005, 14, 452-457.
23. MILLER WR. Uptake and synthesis of steroid hormones by the breast. Endrocrine-Related Cancer 1997, 4: 307-311.
24. SIMPSON ER, MISSO M, HEWITT KN, HILL RA, BOON WC, JONES ME, KOVACIC A, ZHOU J, CLYNE CD. Estrogen - the good, the bad, and the unexpected. Endocrine Reviews 2005, 26: 322-330.
25. REED MJ. Role of enzymes and tissue-specific actions of steroids. Maturitas 2004, 48 Suppl: S18-S23.
26. PASQUALINI JR, CHETRITE GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Molec. Biol. 2005, 93, 221-236.
27. MILLER WR, MULLEN P, SOURDAINE P, WATSON C, DIXON JM, TELFORD J. Regulation of aromatase activity within the breast. J. Steroid Biochem. Molec. Biol. 1997, 61: 193-202.
28. HARADA N. Aromatase and intracrinology of estrogen in hormone-dependent tumors. Oncology 1999, 57: 7-16.
29. SUZUKI T, DARNEL AD, AKAHIRA JI, ARIGA N, OGAWA S, KANEKO C, TAKEYAMA J, MORIYA T, SASANO H. 5α-reductases in human breast carcinoma : possible modulator of in situ androgenic actions. J. Clin. Endocrinol. Metab 2001, 86: 2250-2257.
30. WONG YC, XIE B. The role of androgens in mammary carcinogenesis. IT. J. Anat. Embryol. 2001, 106: 111-125.
31. DORGAN JF, STANCZYK FZ, LONGCOPE C, STEPHENSON H, CHANG L, MILLER R, FRANZ C, FALK RT, KAHLE L. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3β, 17β-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol. Biomark. Prev. 1997, 6: 177-181.
32. MAGGIOLINI M, DONZE O, JEANNIN E, ANDRO S, PICARD D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α1. Cancer Res. 1999, 59: 4864-4869.
33. RODY A, DIALLO R, POREMBA C, WUELFING P, KISSLER S, SOLBACH C, KAUFMANN M, JACKISCH C. Androgen receptor expression in ductal carcinoma in situ of the breast. Appl. Immunohistochem Mol. Morphol. 2005, 13: 25-29.
34. LIAO DJ, DICKSON RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J. Steroid Biochem. Mol. Biol. 2002, 80: 175-189.
35. BAGHAEI F, ROSMON R, WESTBERG I, HELLSTRAND M, ERIKSSON E, HOLM G, BJORNTORP P. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women. Obes. Res. 2003, 11: 578-585.
36. LILLIE EO, BERSTEIN L, INGLES SA, GAUDERMAN WJ, RIVAS GE, GAGALANG V, KRONTIRIS T, URSIN G. Polymorphism in the androgen receptor and mammographic density in women taking and not taking estrogen and progestin therapy. Cancer Res. 2004, 64: 1237-1241.
37. GOMPEL A, CHAOUAT M, HUGOL D, FORGEZ P. Steroidal hormones and proliferation, differentiation and apoptosis in breast cells. Maturitas 2004, 49: 16-24.
38. CONNEELY OM, JERECEVIC BM, LYDON JP. Progesterone receptors in mammary gland development and tumorigenesis. J. Mammary Gland Biol. Neoplasia 2003; 205-214.
39. ISMAIL PM, AMATO P, SOYAL SM, DEMAYO FJ, CONNEELY OM, MALLEY BO, LYNDON JP. Progesterone involvement in breast development and tumorigenesis - as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 2003; 68, 779-787.
40. CARVAJAL A, ESPINOZA N, KATO S, PINTO M, SADARAGANI A, MONSO C, ARANDA E, VILLADON M, RICHER JK, HORWITZ KB, BROSENS JJ, OWEN GI. Progesterone pre-treatment potentiates EGF pathway signaling in the breast cancer cell line ZR-75. Breast Cancer Res. Treat. 2005, 94 : 171-183.
41. MOTE PA, BARTOW S, TRAN N, CLARKE CL. Loos of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res. Treat. 2002, 72, 163-172.
42. HORIUCHI S, KATO K, SUGA S, TAKAHASHI A, UEOKA Y, ARIMA T, NISHIDA JI, HACHISUGA T, KAWARABAYASHI T, WAKE N. Expression of progesterone receptor B is associated with G0/G1 arrest of the cell cycle and growth inhibition in NIH3T3 cells. Experimental Cell Res. 2005, 305, 233-243.
43. LIANG Y, HYDER SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells : paracrine and autocrine effects. Endrocrinology 2005, 146, 3632-3641.
44. WU J, RICHER J, HORWITZ KB, HYDER SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells : preferential regulation by progesterone receptor B. Cancer Res. 2004, 63, 2238-2244.
45. RAAFAT AM, HOFSETH LJ, HASLAM SZ. Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model. Am. J. Obstet. Gynecol. 2001, 184 : 340-349.
46. RAAFAT AM, LI S, BENNETT JM, HOFSETH LJ, HASLAM SZ. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model.J. Cell. Physiol. 2001, 187: 81-89.
47. SEEGER H, MUECK AO, LIPPERT TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. Horm. Metab. Rest. 2000, 32 : 436-439.
48. HOFSETH LJ, RAAFAT AM, OSUCH JR, PATHAK DR, SLOMSKI CA, HASLAM SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 1999, 84 : 4559-4565.
49. MA Y, KATIYAR P, JONES L.P, FAN S, ZHANG Y, FIRTH P.A, ROSEN E.M. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol. 2006, 20, 14-34.
50. JOVANOVIC POOLE A, LI Y, KIM Y, LIN SCJ, LEE WH, LEE EYHP. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antogonist. Science 2006, 314, 1467-1470.
51. CATHERINO WH, JENG MH, JORDAN VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br. J. Cancer 1993, 67 : 945-952.
52. CAMPAGNOLI C, CLAVEL-CHAPELON F, KAAKS R, PERIS C, BERRINO F. Progestatifs et progestérone dans le traitement hormonal substitutif et risque de cancer du sein. J. Steroid Biochem. Mol. Biol. 2005, 96 : 1-15.
53. PASQUALINI JR. The selective estrogen enzyme modulators in breast cancer : a review. Biochimica et Biophysica Acta 2004, 1654 : 123-143.
54. PASQUALINI JR, CHETREITE GS. Reent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 2005, 93 : 221-236.
55. PASQUALINI J.R, CHETREITE G.S. Estradiol as an anti-aromatase agent in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2006, 98 : 12-17.
56. CHETRITE GS, PARIS J, SHIELDS-BOTELLA J, PHILIPPE JC, PASQUALINI JR. Effect of nomegestrol acetate on human estrogen sulfotransferase activity in the hormone-dependent MCF-7 and 7-47D breast cancer cell lines. Anticancer Research 2003, 23 : 4651-4656.
57. CHETRITE GS, THOLDE HH, PHILIPPE JC, PASQUALINI JR. Dydrogesterone (Duphaston) and its 20-dihydro-derivative as selective estrogen enzyme modulators in human breast cancer cell lines. Effect on sulfatase and on 17β-hydroxysteroid dehydrogenase (17β-HSD) activity. Anticancer Research 2004, 24 : 1433-1438.
58. ZHENG W, XIE D, CERHAN JR, SELLERS TA, WEN W, FOLSOM AR. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 2001, 10 : 89-94.
59. WOOD CE, REGISTER TC, LEES CJ, CHEN H, KIMREY S, CLINE JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Rest. Treat. 2006.
60. STEFANICK ML, ANDERSON GL, MARGOLIS KL, HENDRIX SL, RODABOUGH RJ, PASKETT ED, LANE DS, HUBBELL FA, ASSAF AR, SARTO GE, SCHENKEN RS, YASMEEN S, LESSIN L, CHLEBOWSKI RT. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. Jama, 2006, 14, 1647-1657.
61. CHEN WY, MANSON JE, HANKINSON SE, ROSNER B, HOLMES MD, WILLETT WC, COLDITZ GA. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch. Intern. Med. 2006, 166, 1027-1032.
62. LI CI, MALONE KE, PORTER PL, WEISS NS, TANG MT, CUSHING-HAUGEN KL, DALING JR. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. Jama 2003, 24 : 3254-3263.
63. CLAVEL-CHAPELON F, FOURNIER A, BERRINO F, RIBOLI E, AVENEL V. Risque de cancer du sein dans la cohorte E3N-EPIC, en fonction des différents types de traitement hormonal substitutif. Int. J. Cancer 2005, 114 : 448-454.
64. SCHINDLER AE, CAMPAGNOLI C, DRUCKMANN R, HUBER J, PASQUALINI JR, SCHWEPPE KW, THIJSSEN JHH. Classification and phamacology of progestins. Maturitas 2003, 46S1 : S7-S16.
65. PASQUALINI JR. Differential effects of progestins on breast tissue enzymes. Maturitas 2003. 46S1 : S45-S154.
66. FRANKE HR, VERMES I. Diffential effects of progestogens on breast cancer cell lines. Maturitas 2003, 46S1 : S55-S58.
67. DRUCKMANN R. Progestins and their effects on the breast. Maturitas 2003, 46S1 : S59-S69.
68. DESREUX J, GOFFIN F, BELIARD A, MASSON V, NOËL A, KEBERS F, THOMAS JL, FOIDART JM. L'apoptose mammaire dans le sein normal et en pathologic Ref. Gynecol. Obst. 1999, 6 : 33-40.
69. GREEN KA, STREULI CH. Apoptosis regulation in the mammary gland. Cell. Mol. Life Sci. 2004, 61 : 1867-1883.
70. PLU-BUREAU G, THALABARD JC, SITRUK-WARE R, ASSELAIN B, MAUVAIS- JARVIS P. Cyclical mastalgia as a marker of breast cancer susceptibility : results of a case-control study among french women. Br. J. Cancer 1992, 65 : 945-949.
71. GOODWIN PJ, DE BOER G, CLARK RM, CATTON P, REDWOOD S, HOOD N, BOYD NF. Cyclical mastopathy and premenopausal breast cancer risk. Results of a cas-control study. Breast Cancer Res. Treat. 1995, 33 : 61-73.
72. AIELLO EJ, BUIST DSM, WHITE E, PORTER PL. Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol. Biomark. Prev. 2005, 14 : 662-668.
73. BOYD NF, ROMMENS JM, VOGT K, LEE V, HOPPER JL, YAFFE MJ, PATERSON AD. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol. 2005, 10 : 798-808.
74. JUNKERMANN H, VON HOLST T, LANG E, RAKOV V. Influence of different HRT regimens on mammographic density. Maturitas 2005, 50 : 105-110.
75. LAHMANN PH, HOFFMANN K, ALLEN N. Body size and breast cancer risk : findings from the European Prospective Investigatin into Cancer and Nutrition (EPIC). Int. J. Cancer 2004, 111 : 762-771.
76. TEHARD B, LAHMANN PH, RIBOLI E, CLAVEL-CHAPELON F. Anthropometry, breast cancer and menopausal status : use of repeated measurements over 10 years of follow-up-results of the french E3N women's cohort study. Int. J. Cancer 2004, 111 : 264-269.
77. MAGNUSSON C, BARON J, PERSSON I. Body size in different periods of life and breast cancer risk in postmenopausal women. Int. J. Cancer 1998, 76 : 29-34.
78. BERGSTROM A, PISANI P, TENET V. Overweight as an avoidable cause of cancer in Europe. Int. J. Cancer 2001, 91 : 421-430.
79. ENDOGENOUS HORMONES BEAST CANCER COLLABORATIVE GROUP. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 2003, 95 : 1218-1826.
80. SINGLETARY KW, GAPSTUR SM. Alcohol and breast cancer : review of epidemiologic and experimental evidence and potential mechanisms. Jama 2001, 286 : 2143-2151.
81. COLLABORATIVE GROUP ON HORMONAL FACTORS IN BREAST CANCER. Alcohol, tobacco and beast cancer : collaborative reanalysis of individual data from 53 epidemiological studies, including 58.515 women with breast cancer and 95.067 women without the disease. Br. J. Cancer 2002, 87 : 1234-1245.
82. WILLETT WC, STAMPFER MJ, COLDITZ GA. Moderate alcohol consuption and the risk of breast cancer. N. Engl. J. Med. 1987, 316: 1174-1180.
83. TERRY P, SUZUKI R, HU FB, WOLK A. A prospective study of major dietary patterns and the risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2001, 10 : 1281-1285.
84. ZHANG S, HUNTER DJ, HANKINSON SE. A prospective study of folate intake and the risk of breast cancer. Jama 1999, 281 : 1632-1637.
85. SELLERS TA, KUSHI LH, CERHAN JR. Dietary folate intake alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology 2001, 12 : 420-428.
86. ROHAN TE, JAIN MG, HOWE GR, MILLER AB. Dietary folate consumption and breast cancer risk. J. Natl. Cancer Inst. 2000, 92 : 266-269.
87. REYNOLDS P, HURLEY S, GOLDBERG DE. Active smoking, household passive smoking, and brest cancer : evidence from the California Teachers Study. J. Natl. Cancer Inst. 2004, 96 : 29-37.
88. FERLAY J, BRAY F, PISANI P, PARKIN DM. GLOBOCAN 2002 : cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5, version 2.0. Lyon : IARC Press 2004.